Ocular Therapeutix (OCUL) reported a Q3 net loss Thursday of $0.22 per diluted share, narrowing from a loss of $0.25 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.24.

Revenue for the quarter ended Sept. 30 was $15.4 million, up from $15.1 million a year earlier.

Analysts surveyed by Capital IQ expected $17.1 million.

Cash and cash equivalents totaled $427.2 million as of Sept. 30, up from $195.8 million on Dec. 31, which the company said it believes is sufficient to fund operations into 2028.